Table 1 Correlation between reduction in tumour size and reduction in circulating tumour cells with treatment
Patient group | Tumour size before treatment (mm) | Tumour size at surgery (mm) | Fold reduction in circulating cell numbers |
|---|---|---|---|
Patients receiving dose-dense epirubicin | 25 × 25 × 25 | 12 × 12 × 12 | 9.09 |
25 × 20 × 25 | 9 × 12 × 8 + small remnant tumour structures | 14.70 | |
70 × 50 × 25 | 70 × 50 × 20 | 1.00 | |
85 × 85 × 85 | 38 × 26 × 22 | 666.67 | |
50 × 50 × 50 | 0 | 111.11 | |
60 × 60 × 60 | ND | 16.00 | |
35 × 35 × 20 | 11 × 11 × 11 | 31.00 | |
25 × 25 × 25 | 20 × 20 × 20 | 3.80 | |
Patients receving epirubicin/cyclophosphamide without herceptin | 22 × 15 × 28 | 13 × 10 × 8 | 3.70 |
50 × 50 × 50 | 15 × 10 × 12 | 50.00 | |
25 × 25 × 25 + DCIS | 7 × 7 × 7 + small remnant tumour structures | 18.18 | |
40 × 30 × 30 | 27 × 27 × 27 | 3.68 | |
36 × 40 × 26 | 15 × 15 | 46.00 | |
50 × 30 | 25 × 35 × 17 | 0.80 | |
15 × 11 × 13 and 8 × 9 × 8 | 17 × 15 × 9 | 23.00 | |
Patients receiving epirubicin/cyclophosphamide with herceptin | 80 × 70 × 70 | Not yet available | |
50 × 30 × 40 | 0 | 1.40 | |
20 × 32 × 20 | 5 × 5 × 5 | 0.53 | |
38 × 26 × 37 | Right: 26 × 17; left: 17 × 13 and 16 × 9 and 7 × 6 and 3 × 5 | 37.60 | |
20 × 24 × 20 | 0 | 9.20 | |
32 × 18 × 20 | 0 | 0.50 | |
20 × 15 × 20 | 0 | 71.67 |